Recent News

• 04.02.2025 - Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
• 04.02.2025 - Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
• 03.27.2025 - Acumen Pharma FY 2024 Conference Call and Webcast
• 03.27.2025 - Acumen Pharma FY 2024 Conference Call and Webcast
• 03.27.2025 - Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
• 03.27.2025 - Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
• 03.26.2025 - Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
• 03.26.2025 - Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
• 03.20.2025 - Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
• 03.20.2025 - Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Recent Filings

• 03.31.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - 8-K Current report
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - S-8 Securities to be offered to employees in employee benefit plans